Date: 2013-12-04
Type of information: Licensing agreement
Compound: SPS (Stabilizing and Protecting Solutions) technology platform for veterinarian vaccine
Company: Leukocare (Germany) undisclosed top-tier global provider of animal health products
Therapeutic area: Veterinary medicine
Type agreement: licensing
Action mechanism:
Disease: undisclosed infectious disease
Details: * On December 4, 2013, Leukocare, a provider of stabilizing and protecting formulation technologies for proteins and other biologics, has announced the signing of a license agreement with a top-tier global provider of animal health products. Subject to the terms of the agreement, Leukocare has granted a license option that will ensure worldwide exclusive access for the specific indication to Leukocare’s SPS (Stabilizing and Protecting Solutions) proprietary relevant patents and know-how. In the course of the announced collaboration,
Leukocare and its partner have optimized for storage stability a previously commercialised and successfully marketed vaccine.
Clinical trials in target species ongoing, product approval and market launch expected for 2016.Preclinical studies have demonstrated that Leukocare’s SPS increase significantly the stability of the viral antigens of the vaccine that currently has to be stored at 4°C. The optimized next product generation is expected to be stable at room temperature.
Currently, clinical trials in target species are performed by SPS (Stabilizing and Protecting Solutions) proprietary relevant patents and know-how’s partner for product approval. The development process is expected to be completed in 2-3 years and market launch of the modified product is scheduled for 2016.
Financial terms:
Latest news:
